版本:
中国

BRIEF-Ignyta to explore strategic options for Taladegib through amendment of Taladegib license agreement with Lilly

March 23 Ignyta Inc

* Ignyta announces exploration of strategic options for Taladegib, enabled by amendment of Taladegib license agreement with Lilly

* Ignyta - agreement amends and restates prior license, development and commercialization agreement, dated November 6, 2015, by and between Ignyta, Lilly

* Ignyta Inc - entered into amended , restated license, development, commercialization agreement with Eli Lilly and company for Taladegib Oncology program Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐